Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

507
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
507
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

1.1K
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glucagon-Like Peptide-1 Receptor Agonists in Inflammatory Bowel Disease: A Narrative Review.

Gastro hep advances·2026
Same author

Risk of Myeloproliferative Neoplasms in Patients With Inflammatory Bowel Disease and Impact on Outcomes: A Multi-Centre Matched Analysis.

Alimentary pharmacology & therapeutics·2026
Same author

Respiratory syncytial virus incidence and clinical outcomes in patients with inflammatory bowel disease: a National Veterans Affairs cohort study.

Inflammatory bowel diseases·2026
Same author

Outcomes in adult liver transplant patients receiving recombinant herpes zoster vaccine.

Vaccine·2026
Same author

Guidelines in Practice: Preventive Care in Inflammatory Bowel Disease.

The American journal of gastroenterology·2026
Same author

Epstein-Barr Virus Positive Diffuse Large B-cell lymphoma Involving the Colon.

Gastrointestinal endoscopy·2026

Related Experiment Video

Updated: Jan 8, 2026

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

798

Abnormal MUC1 Expression as a Biomarker for Pouchitis.

Caroline G Olson1, Fadi F Francis1, Irene K Yan2,3

  • 1Division of Gastroenterology and Hepatology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL, USA.

Digestive Diseases and Sciences
|December 21, 2025
PubMed
Summary
This summary is machine-generated.

Abnormal MUC1 glycoprotein is overexpressed in ulcerative colitis (UC) patients with pouchitis after ileal-anal anastomosis (IPAA). This abnormal MUC1 increases with pouchitis severity, potentially serving as a biomarker.

Keywords:
MUC1PouchitisUlcerative colitis

More Related Videos

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

925

Related Experiment Videos

Last Updated: Jan 8, 2026

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment
04:05

Author Spotlight: Developing a Rat Model for Pouchitis Research and Treatment

Published on: May 31, 2024

798
Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis
07:05

Important Endpoints and Proliferative Markers to Assess Small Intestinal Injury and Adaptation using a Mouse Model of Chemotherapy-Induced Mucositis

Published on: May 12, 2019

6.5K
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
05:05

Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid

Published on: June 17, 2025

925

Area of Science:

  • Gastroenterology
  • Immunology
  • Molecular Biology

Background:

  • Pouchitis is a common complication following ileal-anal pouch anastomosis (IPAA) in ulcerative colitis (UC) patients.
  • Aberrant glycosylation of MUC1 glycoprotein occurs during inflammation, potentially disrupting the mucus barrier.
  • Understanding MUC1 expression patterns can elucidate pouchitis pathogenesis.

Purpose of the Study:

  • To investigate MUC1 expression patterns in pouch mucosa of UC patients with varying degrees of pouchitis.
  • To compare MUC1 expression in UC patients with pouchitis to familial adenomatous polyposis (FAP) patients without pouchitis.

Main Methods:

  • Analysis of archived J-pouch biopsies from UC/IPAA and FAP/IPAA patients.
  • Immunohistochemical staining for abnormal hypoglycosylated MUC1.
  • Histological grading of inflammation using the Nancy Histological Index.

Main Results:

  • Significantly increased abnormal hypoglycosylated MUC1 expression was observed in UC/IPAA patients compared to FAP/IPAA patients.
  • MUC1 expression levels correlated positively with the severity of pouchitis in UC patients.
  • Minimal abnormal MUC1 was detected in patients without pouchitis or those with FAP.

Conclusions:

  • Abnormal hypoglycosylated MUC1 is overexpressed in the ileal mucosa of UC patients with pouchitis.
  • The degree of MUC1 overexpression is proportional to the severity of pouchitis.
  • Hypoglycosylated MUC1 shows potential as a biomarker for severe pouchitis.